Intravitreal methotrexate for the treatment of proliferative vitreoretinopathy
JournalBMJ Open Ophthalmology
PublisherBMJ Publishing Group
MetadataShow full item record
AbstractBackground/aims Preventing and treating proliferative vitreoretinopathy (PVR) remain a serious challenge for vitreoretinal surgeons. PVR is a devastating complication of retinal detachment that results in recurrent detachment and limits visual recovery. At present, there is no effective treatment for PVR. Materials and methods A retrospective review was performed on a cohort of five consecutive eyes with severe PVR and recurrent retinal detachment that were treated with relaxing retinectomy, extended perfluorocarbon liquid tamponade (4-5 weeks) and a series of intravitreal methotrexate (MTX) injections (100-200 ?g/0.05 mL for 10 weeks). Results All five patients remained reattached (100%) with 11-27 months of follow-up (mean = 17.4). 4 eyes recovered ambulatory vision (>20/200) with normal intraocular pressure and non-fibrotic laser scars along with the relaxing retinectomy. The initial patient remained reattached, but only had hand motions vision. The only adverse effect noted was mild superficial punctate keratopathy in one patient. Conclusion This small, retrospective study suggests that a series of MTX injections may be beneficial for treating complex retinal detachment caused by PVR. Further study is indicated. Copyright 2019 Author(s).
Identifier to cite or link to this itemhttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85066761374&doi=10.1136%2fbmjophth-2019-000293&partnerID=40&md5=2aad680db2b4d3fee1b41094473da20b; http://hdl.handle.net/10713/10248